Role of EEG in Differentiation Between Ischemic and Hemorrhagic Stroke
NCT ID: NCT06984965
Last Updated: 2025-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2025-06-30
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker for Rapid Diagnosis of Hemispheric Stroke
NCT00916864
Accuracy of Transcranial Colour Coded Duplex in Comparing With CT Angiography
NCT06920303
Cognitive Impairment and Outcome of Acute Ischemic Stroke.
NCT04235920
Imaging and Serological Biomarkers of Autonomic Dysfunction After Ischemic Stroke
NCT06740942
Cranial Temperature Early Diagnose Hemorrhagic and Ischemic Stroke
NCT02601183
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
EEG patterns depend on the size and location of acute ischemic stroke, including generalized or focal slowing or both and epileptiform discharges. Abnormal neuronal activity is determined by comparing a part of the patient's brain not affected by stroke to a part of the patient's brain affected by stroke. Moreover, Abnormal blood flow is interpreted by comparing the abnormal EEG patterns in the areas of infarctions or hemorrhage to the normal brain tissue signals. The aim is to compare electric waveforms from an EEG device between patients with acute ischemic and acute hemorrhagic stroke (at baseline which is within 72 hours of the onset of acute ischemic and acute hemorrhagic stroke and through study completion, an average of 3 to 6 months).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ischaemic Stroke Group
Patients with ischemic arteria cerebri media infarct confirmed by MRI.
No interventions assigned to this group
Haemorrhagic Stroke Group
Patients with spontaneous intraparenchymal bleeding confirmed by CT.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute Ischemic stroke: ischemic arteria cerebri media infarct confirmed by MRI.
* Acute Hemorrhagic stroke: spontaneous intraparenchymal bleeding confirmed by CT.
* Stroke onset \<72 hours before expected time of performing EEG.
* First-ever ischemic stroke.
* Measurable deficit on the National Institute of Health Stroke Scale (NIHSS).
* Able to give and sign informed consent.
Exclusion Criteria
* Greater than 72 hours past the initial insult.
* Patients with subarachnoid haemorrhage, traumatic haemorrhage (epidural/subdural bleeding), cerebral venous sinus thrombosis, indication for urgent neurosurgical intervention.
* History of other central nervous system diseases.
* Any signs unfit for MRI/EEG scan.
* Injury or active infection of electrode cap placement area.
* Claustrophobia; recognition disorder.
* Known skull defect or head trauma.
* Previous neurological procedure (metallic implant, brain pace, cranial operation history).
* Significant physical impairment that would restrict the ability to use the portable EEG devices.
* Presence of malignancy or systemic rheumatic disease
* Non-stroke disease or lesion affecting the sensorimotor system.
* Alcohol or drug addiction.
* Presence of pump/shunt.
* Presence of Malignancy.
* Presence of severe cognitive impairment.
* History of epilepsy or taking medication due to epilepsy.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gena ELassall
Residant at Neurology Department, Faculty of Medicine, Assiut University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neurology Department, Faculty of Medicine, Assiut University
Asyut, Asyut Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Gena ELassall
Role: primary
Gena ELassall
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04-2024-200998
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.